B U Mueller
Affiliation: Harvard University
- Cancers in human immunodeficiency virus-infected childrenB U Mueller
Harvard Medical School, Children s Hospital, Boston, MA 02115, USA
J Natl Cancer Inst Monogr . 1998..Furthermore, insights gained from the study and treatment of this very challenging group of patients may benefit other immunocompromised hosts as well as increase our understanding of oncogenesis in general...
- Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected childrenB U Mueller
Pediatric Branch and Biostatistics and Data Management Section, National Cancer Institute, Bethesda, Maryland, USA
Antimicrob Agents Chemother 42:3187-92. 1998..A limited-sampling strategy was developed to estimate the area under the concentration-time curve for concentrations in serum at 2 and 6 h...
- The infant with a vascular tumorB U Mueller
Department of Medicine, Harvard Medical School, Children s Hospital, Boston, MA 02115, USA
Semin Perinatol 23:332-40. 1999..Vascular lesions should be biopsied if there is any suspicion of malignancy...
- Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosingB U Mueller
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Antimicrob Agents Chemother 42:1815-8. 1998..The pharmacokinetic profile of KNI-272 may limit the drug's efficacy in vivo. It appears that KNI-272 will play a limited role in the treatment of HIV-infected children...
- Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDSC Chougnet
Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
J Infect Dis 184:201-5. 2001..These findings suggest that long-term nonsuppressive antiretroviral therapy can induce limited improvement in immune function in pediatric AIDS patients and that the effect of suppressive treatments should be investigated...
- Kinetics of HIV-1 RNA concentration changes in pediatric patientsS L Zeichner
HIV and AIDS Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
Pathobiology 64:289-94. 1996..These findings may have implications for understanding HIV-1 pathogenesis and the development of therapeutic protocols...
- Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacyM A Polis
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10, Room 11C103, National Institutes of Health NIH, Bethesda, MD 20892, USA
Lancet 358:1760-5. 2001..75 or 1.00 log, respectively. We investigated the possibility of assessing drug efficacy from measurements of plasma HIV-1 concentrations made during the first week on therapy...
- Cytomegalovirus infection in children with human immunodeficiency virus infectionB J Kitchen
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Pediatr Infect Dis J 16:358-63. 1997..To determine retrospectively the prevalence of positive cytomegalovirus (CMV) cultures in pediatric patients with human immunodeficiency virus infection...
- Cancer in human immunodeficiency virus-infected children: a case series from the Children's Cancer Group and the National Cancer InstituteM O Granovsky
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
J Clin Oncol 16:1729-35. 1998..To describe the spectrum of malignancies in human immunodeficiency virus (HIV)-infected children and the clinical outcome of patients with these tumors...
- Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudineS Jankelevich
HIV and AIDS Malignancy Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
J Infect Dis 183:1116-20. 2001..CD4+ CD45RA+ (naive) T cells were the major contributor to CD4+ T cell expansion. Continued long-term immunologic benefit may be experienced by a subset of children, despite only transient virologic suppression...
- HIV-associated malignancies in childrenB U Mueller
Department of Pediatrics, Harvard Medical School, Children s Hospital, Boston, Massachusetts, USA
AIDS Patient Care STDS 13:527-33. 1999..Such regimens may be complicated, however, by multiple HIV-associated organ dysfunctions, drug interactions, and infectious complications secondary to severe immunosuppression...
- Cancers in children infected with the human immunodeficiency virusB U Mueller
Harvard Medical School, Hunnewell Children s Hospital, Boston, Massachusetts 02115, USA
Oncologist 4:309-17. 1999..This article provides an overview of epidemiology and clinical and pathological presentations, as well as preliminary data regarding treatment options in children with HIV-associated malignancies...
- Prevention of red cell dehydration: a possible new treatment for sickle cell diseaseB U Mueller
Children s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Pediatr Pathol Mol Med 20:15-25. 2001..In this brief review, we discuss the pathophysiologic background and explore some new treatment options to prevent vaso-occlusive crises or other problems in this patient population...
- Chemokine gene expression and clonal analysis of B cells in tissues involved by lymphoid interstitial pneumonitis from HIV-infected pediatric patientsJ Teruya-Feldstein
Laboratory of Pathology, Hematopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Mod Pathol 14:929-36. 2001..In addition, LIP may represent an early stage of MALT lymphoma or an immunologic response to a chronic antigenic stimulus that may provide a milieu or microenvironment for the evolution of a monoclonal B-cell population...